---
trial_id: 816
discovery_date: 2022-05-15 20:21:08.571781
date: 2022-05-15 20:21:08.571781
title: "A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis"
summary: |
  <p>EudraCT Number: 2021-005746-15<br />Sponsor Protocol Number: MN43964<br />Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd<br />Start Date: 2022-05-09<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
  Relapsing Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/ES">ES</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005746-15'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2021-005746-15<br />Sponsor Protocol Number: MN43964<br />Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd<br />Start Date: 2022-05-09<br />Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
Relapsing Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063401<br />Term: Primary progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005746-15/ES">ES</a> (Ongoing)</p>